Financial reports
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
ARS
2022 FY
Annual report to shareholders
26 May 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K
2021 FY
Annual report
31 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
Current reports
8-K
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
28 Mar 24
8-K
Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification
13 Mar 24
8-K
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive
4 Mar 24
8-K
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
29 Feb 24
8-K
Other Events
14 Feb 24
8-K
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
1 Feb 24
8-K
Full Data Readout Expected in the Second Half of 2024
18 Jan 24
8-K
Other Events
9 Jan 24
8-K
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
28 Dec 23
8-K
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
19 Dec 23
Registration and prospectus
S-8
Registration of securities for employees
17 Apr 23
424B3
Prospectus supplement
1 Feb 23
S-3
Shelf registration
23 Jan 23
424B4
Prospectus supplement with pricing info
7 Nov 22
S-1/A
IPO registration (amended)
3 Nov 22
FWP
Free writing prospectus
24 Oct 22
S-1/A
IPO registration (amended)
24 Oct 22
S-1
IPO registration
16 Sep 22
S-8
Registration of securities for employees
4 Nov 21
D
$14M in equity / options / securities to be acquired, sold $14M, 12 investors
18 Oct 21
Proxies
DEF 14A
Definitive proxy
26 May 23
PRE 14A
Preliminary proxy
16 May 23
DEF 14A
Definitive proxy
28 Nov 22
PRE 14A
Preliminary proxy
15 Nov 22
DEF 14A
Definitive proxy
18 May 22
PRE 14A
Preliminary proxy
6 May 22
DEF 14A
Definitive proxy
26 Jul 21
DEF 14A
Definitive proxy
15 Jun 21
PRER14A
Preliminary revised proxy
10 Jun 21
PRER14A
Preliminary revised proxy
2 Mar 21
Other
EFFECT
Notice of effectiveness
1 Feb 23
CORRESP
Correspondence with SEC
27 Jan 23
UPLOAD
Letter from SEC
25 Jan 23
EFFECT
Notice of effectiveness
7 Nov 22
CORRESP
Correspondence with SEC
3 Nov 22
CORRESP
Correspondence with SEC
3 Nov 22
UPLOAD
Letter from SEC
22 Sep 22
UPLOAD
Letter from SEC
25 Jun 21
CORRESP
Correspondence with SEC
10 Jun 21
EFFECT
Notice of effectiveness
27 May 21
Ownership